Institut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain; CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.
CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain; Institut d'Investigació Biomèdica Sant Pau (IIB SANT PAU), Barcelona, Spain; Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain.
Biomed Pharmacother. 2023 Aug;164:114976. doi: 10.1016/j.biopha.2023.114976. Epub 2023 Jun 3.
Two human proteins involved in the inflammatory cell death, namely Gasdermin D (GSDMD) and the Mixed Lineage Kinase Domain-Like (MLKL) protein have been engineered to accommodate an efficient ligand of the tumoral cell marker CXCR4, and a set of additional peptide agents that allow their spontaneous self-assembling. Upon production in bacterial cells and further purification, both proteins organized as stable nanoparticles of 46 and 54 nm respectively, that show, in this form, a moderate but dose-dependent cytotoxicity in cell culture. In vivo, and when administered in mouse models of colorectal cancer through repeated doses, the nanoscale forms of tumor-targeted GSDMD and, at a lesser extent, of MLKL promoted CD8 and CD20 lymphocyte infiltration in the tumor and an important reduction of tumor size, in absence of systemic toxicity. The potential of these novel pharmacological agents as anticancer drugs is discussed in the context of synergistic approaches to more effective cancer treatments.
两种参与炎症细胞死亡的人类蛋白,即 Gasdermin D(GSDMD)和混合谱系激酶结构域样(MLKL)蛋白,已被设计为适应肿瘤细胞标志物 CXCR4 的有效配体,以及一组允许其自发自组装的额外肽剂。在细菌细胞中生产并进一步纯化后,两种蛋白质分别自组装为 46nm 和 54nm 的稳定纳米颗粒,以这种形式,在细胞培养中表现出适度但剂量依赖性的细胞毒性。在体内,并且当通过重复剂量施用于结直肠癌的小鼠模型中时,肿瘤靶向的 GSDMD 的纳米级形式,并且在较小程度上,MLKL 促进了肿瘤中 CD8 和 CD20 淋巴细胞的浸润,并重要的是减少了肿瘤的大小,而没有全身毒性。这些新型药理制剂作为抗癌药物的潜力在更有效的癌症治疗协同方法的背景下进行了讨论。